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Abstract Prostate cancer is one of the most common cancers in
men and is the second leading cause of cancer-related deaths in
the USA. Many anti-tumor agents against prostate cancer cells
have been developed, but their unacceptable systemic toxicity to
normal tissues frequently limits their usage in clinics. Several
previous studies have demonstrated that tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL) can induce cell death
in a variety of transformed cells including prostate cancer cells,
but not normal cells. Indole-3-carbinol (I3C), a phytochemical
that is produced in fruits and vegetables, may play an important
role in the prevention of many types of cancer, including hor-
mone-related ones such as breast and prostate cancer. In this
study, we examined the potential sensitizing e¡ects of I3C on
TRAIL-mediated apoptosis in a prostate cancer cell line,
LNCaP. When LNCaP cells were incubated with I3C (either
30 or 90 WM) for 24 h and then treated with TRAIL (100 ng/
ml), enhanced TRAIL-mediated apoptosis was observed. The
enhanced apoptosis measured by poly(ADP-ribose) polymerase
and caspase 3 cleavage. We also observed that loss of cell via-
bility after treatment with I3C/TRAIL is greater compared with
I3C and TRAIL alone. To determine the molecular mechanisms
involved in the enhanced apoptosis, we examined the expression
of two TRAIL death receptors (DR4 and DR5) and two TRAIL
decoy receptors (DcR1 and DcR2). We found that treatment
with I3C induced DR4 and DR5 expression at both transcrip-
tional and translational levels. These ¢ndings suggest that I3C
may be an e¡ective sensitizer of TRAIL treatment against
TRAIL-resistant prostate cancer cell lines such as LNCaP.
5 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Prostate cancer is one of the most common cancers in men
and remains the second leading cause of cancer-related deaths
in the USA. It is estimated that in 2002, 189 000 new cases will
be diagnosed and 30 200 men will die from prostate cancer in
the USA alone [1]. Androgen can regulate programmed cell
death of normal and malignant prostatic cells and its ablation
is still a major therapy for the treatment of androgen-depen-
dent prostatic cancer cells [2^4].
Tumor necrosis factor (TNF)-related apoptosis-inducing li-
gand (TRAIL) is a member of the TNF family and can induce
apoptotic cell death in a variety of cell types including pros-
tate cancer cells [5^14]. The apoptotic signal induced by
TRAIL is transduced by its binding to the death receptors
TRAIL-R1 (designated death receptor 4, DR4) and TRAIL-
R2 (designated death receptor 5, DR5) [15^17]. Both DR4
and DR5 contain a cytoplasmic death domain capable of
engaging the cell suicide apparatus. TRAIL also binds to
antagonistic decoy receptors, TRAIL-R3 (DcR1) and
TRAIL-R4 (DcR2), which inhibit TRAIL signaling [18^22].
Unlike DR4 and DR5, DcR1 does not have a cytoplasmic
domain and DcR2 retains a cytoplasmic fragment containing
a truncated form of the consensus death domain motif [23].
The relative resistance of normal cells to TRAIL has been
explained by the presence of large numbers of decoy receptors
on normal cells [18,19]. Recently, this hypothesis was chal-
lenged based on results showing poor correlations between
DR4, DR5, and DcR1 expression and sensitivity to TRAIL-
induced apoptosis in normal and cancerous breast cell lines
[24]. This discrepancy indicates that other factors such as
death inhibitors (FLIP, FAP-1, or IAP) are also involved in
the di¡erential sensitivity to TRAIL. Several studies also sug-
gest that constitutively active AKT is an important regulator
of TRAIL sensitivity in prostate cancer cells [25^27].
Many anti-tumor drugs or cytokines have been developed
for prostate cancer patients, but their intolerable systemic
toxicity often limits their clinical usage. TRAIL has been a
focus for anti-tumor studies because of its potential low cyto-
toxicity. However, recent studies have revealed that a poly-
histidine-tagged TRAIL induces apoptosis in normal human
hepatocytes in culture [28]. This is probably due to an aber-
rant conformation and subunit structure of TRAIL in the
presence of low zinc concentrations [29]. In contrast, native-
sequence, non-tagged recombinant TRAIL, when produced
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under optimized zinc concentrations, is markedly more active
against tumor cells than the polyhistidine-tagged ligand, but
has minimal toxicity toward human hepatocytes in vitro [29].
Moreover, preclinical studies in mice and primates have
shown that administration of TRAIL can induce apoptosis
in human tumors, but no cytotoxicity to normal organs or
tissue [30]. In addition, unlike TNF and FasL, TRAIL
mRNA is expressed constitutively in many tissues [6,31].
Indole-3-carbinol (I3C), a common phytochemical in the
human diet, is present in all members of the cruciferous veg-
etable family, which includes cabbage, broccoli, Brussels
sprouts, cauli£ower and kale. Recently, it has become clear
that I3C has the potential to prevent and even treat a number
of common cancers, especially those that are estrogen-related
[32^35].
In this study, we examine the potential sensitizing e¡ects of
I3C to TRAIL-mediated apoptosis in human prostate cancer
cells. Thus, we investigated whether I3C can be involved in
the enhancement of apoptosis mediated by TRAIL. The mo-
lecular analysis of I3C’s e¡ect on TRAIL may provide infor-
mation on the molecular mechanisms by which I3C elicits its
biological e¡ects on prostate cancer (LNCaP) cells. Our data
show that I3C is an e¡ective sensitizer to TRAIL-mediated
apoptosis in LNCaP cells. The sensitizing e¡ect of I3C on
TRAIL was associated with the up-regulation of DR4 and
DR5 at both mRNA and protein levels.
2. Materials and methods
2.1. Cell lines and culture
Human prostate cancer cells (DU-145 and LNCaP) were originally
obtained from the American Type Culture Collection (Rockville, MD,
USA). Cells were grown in Dulbecco’s modi¢ed Eagle’s medium for
DU-145 and RPMI 1640 for LNCaP. Culture media were supple-
mented with either 5% (DU-145) or 10% (LNCaP) fetal bovine serum,
L-glutamine (5 mM), non-essential amino acids (5 mM), penicillin (100
U/ml), and streptomycin (100 Wg/ml) (all obtained from Bio Whit-
taker, Walkersville, MD, USA).
2.2. TRAIL preparation
A human soluble TRAIL cDNA fragment (amino acids 114^281)
obtained by reverse transcription polymerase chain reaction (RT-
PCR) was cloned into a prokaryotic expression vector pET-23d (No-
vagen, Madison, WI, USA) to tag the C-terminus with hexahistidine.
Expressed TRAIL protein was puri¢ed using Ni-NTA His-Bind Resin
Super£ow according to the manufacturer’s instructions (Novagen).
2.3. MTT assays
Growth inhibition of TRAIL was evaluated using a 3-[4,5-dime-
thylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay as de-
scribed previously [36]. Brie£y, subcon£uent cells plated on 96-well
tissue culture plates were treated or not with TRAIL for 16 h. MTT
(2 Wg/ml) was added into each well for 4 h. After the medium con-
taining MTT was aspirated, the formazan crystals were dissolved in
120 Wl of dimethyl sulfoxide (DMSO). The absorbance was recorded
using a Dynatech 96-well spectrophotometer at 570 nm, with 630 nm
as the reference wavelength. The wells that contained only medium
and 10 Wl of MTT were used as blanks for the plate reader. Cell
viability was expressed as the amount of dye reduction in treated cells
relative to that of untreated control cells. Four sets of experiments
were performed in 10 wells for each treatment. The data are presented
as the meanPS.D. of triplicate samples from at least three separate
representative experiments and were analyzed by Student’s t-test. A
level of P6 0.05 was accepted as statistically signi¢cant.
2.4. I3C treatment
I3C was purchased from Sigma (St. Louis, MO, USA), dissolved in
95% EtOH and stored at 320‡C before use. In this study we used 30^
90 WM/l for each dose of I3C as previously described [37]. The cells
were seeded at a density of 9U105 cells in a six-well culture dish. After
24 h, cells were treated with 30, 60, or 90 WM of I3C and the control
cells with 95% DMSO.
2.5. Western blotting
Whole cell lysates were prepared and Western blotting was per-
formed as described earlier [38]. Equal aliquots of total cell protein
(50 Wg per lane) were electrophoresed, transferred, and blotted using
the following primary antibodies: DR4, DR5, DcR1 and DcR2 (rab-
bit polyclonal IgG, Alexis Biochemicals, 1:500 dilution), anti-poly-
(ADP-ribose) polymerase (PARP) (H-250, rabbit polyclonal IgG,
Santa Cruz Biotechnology, Santa Cruz, CA, USA, 1:500 dilution),
anti-caspase 3 (H-277, rabbit polyclonal IgG, Santa Cruz Biotechnol-
ogy, 1:1000). L-Tubulin (D-10, mouse monoclonal IgG, Santa Cruz
Biotechnology, 1:500) and L-actin (I-19, rabbit polyclonal IgG, Santa
Cruz Biotechnology, 1:1000) were used to assure equal loadings.
Horseradish peroxidase-conjugated secondary antibodies were pur-
chased from Santa Cruz.
2.6. Isolation of RNA
After cell treatments with I3C (90 WM), the total cellular RNA was
extracted using TRIzol reagents (Life Technologies), according to the
manufacturer’s instructions. Isolated RNA was electrophoresed
through 1.0% agarose-formaldehyde gels to verify the quality of the
RNA.
2.7. Semiquantitative RT-PCR
The ¢rst strand cDNA was generated from 1 Wg of total RNA in a
¢nal volume of 20 Wl using SuperScript II (Life Technologies) and
oligo(dT) primers. One Wl of the diluted cDNA was used for each
PCR reaction. PCR ampli¢cation was performed using a Perkin-El-
mer DNA thermal cycler. The PCR primer sets used in this study
were as follows: DR4 F, 5P-TTG TGT CCA CCA GGA TCT
CA-3P ; DR4 R, 5P-GTC ACT CCA GGG CGT ACA AT-3P ; DR5
F, 5P-AGA GGG ATT GTG TCC ACC TG-3P ; DR5 F, 5P-AAT
CAC CGA CCT TGA CCA TC-3P ; L-actin F, 5P-TAG CGG GGT
TCA CCC ACA CTG TGC CCC ATC TA-3P ; L-actin R, 5P-CTA
GAA GCA TTT GCG GTG GAC CGA TGG AGG G-3P.
To determine the expression level of DR4 and DR5, 1 Wl (out of 20
Wl) of synthesized cDNA was ampli¢ed in a total volume of 50 Wl
containing 200 WM each of all four dNTPs, 2 WM each of death
receptor-speci¢c primer sets, and 1 U of Taq DNA polymerase (Per-
kin-Elmer). PCR conditions were as follows: 1 cycle, 5 min/95‡C; 29
cycles (for DR4 and DR5) or 22 cycles (for L-actin), 1 min/95‡C,
1 min/53‡C and 1 min/72‡C. L-Actin was used as a loading control.
PCR products were analyzed by electrophoresis through 1.0% agarose
gels containing 0.1 mg/ml of ethidium bromide. The gels were photo-
graphed under ultraviolet illumination.
3. Results and discussion
3.1. TRAIL induces apoptosis of human prostate cancer cells
TRAIL has been reported to induce the apoptosis of a
variety of tumor cell types [5^13]. However, the molecular
determinants of TRAIL-induced apoptosis have not been
well characterized in human prostate cancer cells. We used
the human prostate cancer cell lines DU-145 and LNCaP
for this study. When DU-145 cells were treated with 0^400
ng/ml TRAIL for 16 h, the cellular viability decreased in a
dose-dependent manner as determined by a MTT assay (Fig.
1A). Relative viabilities of DU-145 cells treated with TRAIL
(100 ng/ml) for various intervals were also analyzed (Fig. 1B).
Consistent with the results from the MTT assay in Fig. 1A,
approximately 50% of cells were dead by treatment with
TRAIL (100 ng/ml) for 16 h. A time-dependent reduction in
cell survival was observed in TRAIL-treated cells. The mech-
anism of cell death by TRAIL is apoptosis (data not shown).
In contrast to DU-145, LNCaP was relatively resistant to
treatment with TRAIL (Fig. 1A,B). These results are consis-
tent with a previous study showing that LNCaP is TRAIL-
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resistant, while DU-145 is TRAIL-sensitive compared with
LNCaP cells [39].
3.2. Treatment of LNCaP with I3C up-regulates DR4 and DR5
I3C is an active anti-cancer component and is being inves-
tigated as a treatment and for the prevention of a variety of
cancers [32^35]. In order to investigate the potential e¡ects of
the combination of I3C and TRAIL on prostate cancer cell
growth, we ¢rst determined the e¡ect of I3C on growth of
LNCaP cells. While lower doses (30 and 60 WM) of I3C slightly
stimulated proliferation of LNCaP for the ¢rst 2 days, a higher
dose of I3C (90 WM) slightly suppressed cell growth from the
second day of treatment (Fig. 2). The precise mechanism of the
di¡erential growth regulation by various doses of I3C remains
to be determined. Considering that a low dose of I3C (30 WM)
inhibits the growth of PC-3 prostate cancer cells by the induc-
tion of G1 cell cycle arrest, which led to apoptosis [37], LNCaP
is relatively resistant to low doses of I3C.
Recent studies have shown that glucose deprivation and
doxorubicin enhanced TRAIL-induced cytotoxicity in pros-
tate cancer cells [40,41]. Several DNA damaging agents such
as VP-16, CPT-11, and ionizing radiation have been shown to
enhance TRAIL-induced apoptosis in breast cancer cells [42^
45]. In the case of VP-16 [43] and irradiation [42], increased
levels of DR4 and/or DR5 were responsible for the augmen-
tation of TRAIL-induced apoptosis. In our present study, we
determined the e¡ect of I3C on DR4 and DR5 expression and
TRAIL-induced apoptosis of prostate cancer cells. Fig. 3A
demonstrates that treatment of LNCaP cells with 90 WM of
I3C for 24 h increased DR4 and DR5 protein. However, I3C
did not change the expression of the two TRAIL decoy re-
ceptor DcR1 and DcR2. To determine whether the increases
of DR4 and DR5 protein are due to transcriptional regula-
tion, we performed semi-quantitative RT-PCR. Increased lev-
els of DR4 and DR5 mRNA were found in I3C-treated cells
compared to the control (Fig. 3B). Accordingly, I3C up-reg-
ulates DR4 and DR5 at the transcriptional level in LNCaP
cells.
A recent study shows that treatment of I3C inhibits the
phosphorylation and subsequent activation of Akt kinase in
a human prostate cancer cell line, PC-3 [46]. Since constitu-
tively active Akt is an important regulator of TRAIL sensi-
tivity in prostate cancer [25^27], we examined levels of Akt
and its phosphorylation in LNCaP up to 2 days following I3C
treatment and found no signi¢cant change (data not shown).
Fig. 1. TRAIL-induced cytotoxicity in DU-145 and LNCaP cells.
Cells were treated with TRAIL and survival (%) was analyzed by
the tetrazolium conversion assay as described in Section 2. A: Rela-
tive viabilities of DU-145 and LNCaP cells treated with increasing
doses of TRAIL (0^400 ng/ml) for 16 h. B: Relative viabilities of
DU-145 and LNCaP cells treated with TRAIL (100 ng/ml) for vari-
ous intervals. Black bar represents LNCaP and white bar represents
DU-145 cells.
Fig. 2. E¡ects of I3C on cell survival in LNCaP cells. Cells treated with I3C (30, 60, or 90 WM) for 1^3 days were harvested and cell survival
(%) was determined by the tetrazolium conversion assay as described in Section 2.
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Fig. 3. Increased expression of DR4 and DR5 by I3C treatment. A: Cells treated with 90 WM I3C for 24 h were harvested and subjected to
immunoblotting analysis. The levels of two TRAIL receptors, DR4 and DR5, were measured using each antibody described in Section 2. L-Tu-
bulin was used for loading control. B: The change in DR4 and DR5 transcripts was determined by semi-quantitative RT-PCR. Information on
primer sequences for DR4, DR5 and L-actin and RT-PCR conditions is given in Section 2.
Fig. 4. Pretreatment with I3C sensitizes LNCaP cells to TRAIL-mediated apoptosis. A: Cells pretreated with either 30 or 90 WM I3C for 24 h
were exposed to TRAIL (100 ng/ml) for 24 h and stained with Coomassie blue. B: Cells were lysed and subjected to immunoblotting for
PARP and caspase 3. Immunoblots of PARP showed the 116-kDa PARP and the 85-kDa apoptosis-related cleavage fragment. Anti-caspase 3
antibody detected both inactive (32 kDa) and active forms (17 kDa and 12 kDa). L-Actin was used as an internal control protein. C: Surviv-
ability (%) of cells treated with I3C/TRAIL as in A was tested by the tetrazolium conversion assay as described in Section 2. C represents con-
trol cells ; I represents I3C-treated cells ; T represents TRAIL-treated cells.
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3.3. Sequential exposure to I3C followed by TRAIL increases
apoptosis of prostate cancer cells
To determine the functional signi¢cance of I3C-mediated
up-regulation of DR4 and DR5 levels, we compared the ap-
optotic e¡ects of sequential treatment with I3C followed by
TRAIL with the e¡ects of TRAIL alone. Exposure to I3C (30
or 90 WM) for 24 h followed by 100 ng/ml TRAIL for 24 h
induced a higher level of apoptosis of LNCaP cells than ex-
posure to TRAIL alone (Fig. 4A). To con¢rm that the re-
duced cell viability was due to apoptosis, we measured
PARP cleavage. Compared to each agent alone, the sequential
treatment of I3C followed by TRAIL resulted in increased
processing of PARP and caspase 3 (Fig. 3B). Only one form
of PARP (the full size, 116 kDa) protein was found in the
control cells and cells treated with I3C (30 or 90 WM) for 24 h.
This result implies that the reduced survivability observed
following I3C treatment in Fig. 2 may not be due to apopto-
sis; rather it may be due to cell cycle arrest. The full-size
PARP (116 kDa) protein was cleaved to yield an 85-kDa
fragment after treatment with either TRAIL alone or a com-
bination of I3C and TRAIL. The amount of full-size PARP
declined during the combined treatment (I3C+TRAIL) at a
greater rate than with TRAIL alone. We also found that loss
of cell viability was greater than the sum of the viability losses
observed in cultures treated with I3C and TRAIL alone (Fig.
4C). These results show that pretreatment with I3C (even at a
low dose such as 30 WM) can sensitize DU-145 prostate cancer
cells to TRAIL-mediated apoptosis. A recent study demon-
strated that pretreatment of PC-3 with paclitaxel enhanced
TRAIL-induced apoptosis of human prostate cancer cells by
inducing DR4 and 5 protein levels [47].
The present ¢ndings, taken together with earlier ones dem-
onstrating that TRAIL exerts itself relatively selectively in in
vivo anti-cancer activity, suggest that TRAIL could poten-
tially be a promising anti-prostate cancer therapeutic agent.
TRAIL could also be used with chemopreventive agents such
as I3C. By demonstrating that DR4 and DR5 are up-regu-
lated by I3C, the present ¢ndings also highlight the potential
feasibility of TRAIL administration with I3C to maximize the
apoptotic e¡ect against LNCaP cells.
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